Evofem Biosciences, Inc. Affirms 2022 Guidance. Evofem continues to expect net product sales in the range of $30 to $35 million for its 2022 fiscal year, representing 264% to 325% growth year-over-year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.014 USD | +8.70% | -19.54% | -78.12% |
1st Jan change | Capi. | |
---|---|---|
-78.12% | 977K | |
+38.69% | 728B | |
+34.58% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+16.36% | 244B | |
+7.72% | 207B | |
-5.19% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Affirms 2022 Guidance